

PROGRAM



Bio-Neuroscience

Amsterdam, 24th-26th February, 2026

THE GLOBAL SUMMIT FOR LEADERS
AND DECISION-MAKERS IN
NEUROSCIENCES DRUG
DEVELOPMENT

Key Opinion Leaders
Industry Executives
Startups Founders
C-level Executives
Investors



INSIGHT - ACCESS - ENGAGEMENT - IMPACT

AN INITIATIVE OF



CO-ORGANIZED WITH



DAY I

TUESDAY 24 FEB. 2026



Bio-Neuroscience

14:00

COFFEE & REGISTRATION

14:30

Roundtable Networking - Coffee and a Series of Networking Tables

Participant networking at a series of pre-scheduled roundtables for accelerated introductory networking.

15:00

Pre-Summit Roundtable Discussion – Innovation in BoNT Based Therapies for Neurological and Psychiatric Disorders

Stefan König

Eric Finzi

Marc Axel Wollmer

Tillmann Krüger

CEO - Merz Therapeutics

Co-Founder - Healis Therapeutics

Head of department, Department of Old Age Psychiatry - Asklepios Clinic North – Ochsenzoll

Associate Professor, Deputy Head of Department - Psychiatry, Social Psychiatry and Psychotherapy, Head of Section of Clinical Psychology & Sexual Medicine - Hannover Medical School

15:45

COFFEE BREAK

16:00

Welcome to Bio-Neuroscience: Official Inauguration

Christian J Suojanen

Andrea Soto Padilla

CEO – Broadreach Global

Business Development - Amsterdam Neuroscience, Amsterdam UMC

16:15

The need for Innovation in Pre-Clinical and Para-Clinical Models

José Luís Lanciego

Joshua Bagely

Head, Laboratory of Gene Therapy for Parkinson's Disease Head - CIMA, University of Navarra, & President – European Brain Foundation

Chief Scientific Officer - ahead bio AG



Bio-Neuroscience

DAY I

TUESDAY 24 FEB. 2026



Bio-Neuroscience

16:45

Innovation in Biomarkers to accelerate clinical research and improve clinical care

Joachim Reischl

VP & Franchise Head, Neurodegenerative Disease, Center of Innovation - Danaher Diagnostics

Charlotte Teunissen

Professor in Neurochemistry - Amsterdam UMC

17:15

Venture Philanthropy, Charity and Foundation - Financed Neuroscience Drug Development

Giovanna Lalli

Director of Strategy & Operations – LifeArc

Opher Kornfeld

Director, Translational Research and Development - SPARK NS

Lynsey Bilsland

Managing Director of Parkinson's Virtual Biotech - Parkinson's UK

18:00

Welcome Reception Remarks

18:05

WELCOME RECEPTION & NETWORKING



Bio-Neuroscience



Bio-Neuroscience



08:15

REGISTRATION OPENS, COFFEE & NETWORKING

09:00

Opening Remarks

Christian J Suojanen

CEO – Broadreach Global

Pieter van Bokhoven

Chief Scientific Officer - IXA Amsterdam
Neuroscience UMC

09:15

The Regulatory Perspective in Neuroscience Drug Development

Moderator: Philip Scheltens, Managing Partner – EQT Dementia Fund, Partner EQT Life Sciences

Pavel Balabanov

Head of Therapies for Neurological and
Psychiatric Disorders - European Medicines
Agency (EMA)

10:00

Therapeutics Development for Rare Neurological Diseases; Financing, Clinical and Regulatory Challenges and the Patient and Startup Perspective

Discussion Panel

Moderator: Yael Weiss, CEO - Mahzi Therapeutics

A discussion with stakeholders in rare pediatric neurological disease innovation; from rare families developing therapies, to KOL collaborators and specialized industry partners.

Stuart Cobb

Chief Scientific Officer - Neurogene Inc; Principal
Investigator - The University of Edinburgh

Andy Stevenson

Clinical Trial Lead - Reverse Rett

10:45

NETWORKING COFFEE BREAK

11:15

The Investment Bank Perspective: Navigating the State of Capital Markets and M&A as it impacts Neuroscience Drug Development

Moderator: Bruce Leuchter, President & CEO - Neurvati Neurosciences

Kevin Sheridan

Joint Global Head of Healthcare Investment
Banking - Jefferies LLC

Eric Stewart

Senior Managing Director, Healthcare Mergers
& Acquisitions - Leerink Partners

Sven Pfeiffer

Partner, Strategic Advisory Group - PJT Partners





12:00

Investor Session – The current Investment Landscape for CNS Neuroscience Drug Development

In light of evolving geopolitical, market, and regulatory conditions - what does it mean for private biotech?

Moderator: Hakan Goker, Managing Director & Head of Life Sciences – M-Ventures

Thomas Michael Thestrup

Senior Principal - Angelini Ventures

Henriette Richter

Managing Partner - Sofinnova Partners

Joao Barbosa da Silva

Investor - re.Mind Capital

Keno Gutierrez

General Partner - BioGeneration Ventures (BGV)

12:45

LUNCH & NETWORKING BREAK - HOSTED BY MERZ THERAPEUTICS



THERAPEUTICS

Better outcomes for more patients.

14:00

Fireside Chat – A Strategic Venture to develop a Disease Modifying Therapy for GBA Parkinson's Disease

Moderator: Kees Been, CEO, Kynexis Therapeutics

António Portela

CEO - BIAL

14:45

Neuroinflammation; tackling indications from MS to PD and AD

Key advances, core challenges, and strategies going forward in current market conditions.

Jing Wang

Co-Founder & Chief Executive Officer - Myrobalan Therapeutics

Marcelo Bigal

President & Chief Executive Officer - Ventus Therapeutics

Niels Plath

Chief Scientific Officer – Muna Therapeutics

Christian Mirescu

Chief Scientific Officer – Monument Biosciences

15:30

NETWORKING COFFEE BREAK





16:00

Pricing, Reimbursement, and Survival for Neuroscience Therapeutics
Navigating the policy tightrope, the investor and biotech perspectives, and strategies and innovative models for a new era.

Alexander Natz

Secretary General - European Confederation of
Pharmaceutical Entrepreneurs (EUCOPE)

Silvia Chirolì

Head of Pricing & Market Access EMEA – ArgenX

16:45

COMPANY PITCH SESSION

Selected companies present to an industry & investor panel

17:45

END OF DAY II & NETWORKING RECEPTION – HOSTED BY DANAHER





08:15

REGISTRATION OPENS, COFFEE & NETWORKING

09:00

Opening Remarks

09:15

Keynote II – Engineering AAVs for human CNS Gene Therapy

Ben Deverman

Director, Vector Engineering at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard

10:00

Gene therapy 2.0 in Neuroscience

The evolution of gene therapies, current approaches, opportunities and challenges from the scientific, clinical, regulatory and market perspectives.

Moderator: Robert Thorne, Denali Fellow – Denali Therapeutics, President - International Brain Barriers Society (IBBS)

Alex Bloom

CTO - AviadoBio

Andrew Steinsapir

Acting CTO - Apertura Gene Therapy, & Director, Gene Therapy Program Lead - Deerfield Management

Marco Weinberg

Senior Vice President, Head of Research, uniQur

Sander van Deventer

President R&D, VectorY Therapeutics

10:45

NETWORKING COFFEE BREAK

11:15

Fireside Chat – Anatomy of a deal; Discussing the Angelini Pharma and GRIN Therapeutics deal, one year in

Moderator: Christian J. Suojanen, CEO – Broadreach Global

Jacopo Andreose

CEO - Angelini Pharma S.p.A.

Bruce Leuchter

President & CEO - Neurvati Neurosciences





12:00

Novel modalities, from Oligonucleotides to RNA Therapeutics in CNS Rare Diseases: Science, Approvals, Approaches and Deals.

Maria Luisa Pineda

CEO & Co-Founder - Envisagenics

Tarek Samad

Senior Vice President & Global Head of Research – Lundbeck

Vikas Sharma

Chief Business Officer – QurAlis

12:45

LUNCH & NETWORKING BREAK

14:00

COMPANY PITCH SESSION

Selected companies present to an industry & investor panel

14:45

Industry Panel - Partnering With Industry

Jenny Laird

VP, Business Development Neuroscience - Eli Lilly

Richard Reschen

Director, Business Development & Licensing – MSD

Christian Thomsen

Global External CNS Research – Boehringer Ingelheim

Karen LaRochelle

Global Head of Business Strategy & Portfolio Innovation – Merz Therapeutics

Marta Helena Lesko

VP, Head of Neurology and Immunology Business Development - Merck Group

15:45

Bio-Neuroscience Awards

Company Pitch Awards

16:00

Closing Remarks

16:15

END OF SUMMIT - NETWORKING RECEPTION



THANK YOU TO OUR SPONSORS

Gold Sponsors



THERAPEUTICS

Better outcomes for more patients.

Founding Sponsors



Bronze Sponsors



scontox



Catalent
Pharma Services

PsychoGenics
Transforming CNS Discovery

Partners

•EFFECTIA
Consultoria Estratégica

An Initiative of:



Co-Organized with:

